Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
Phase 3
Active, not recruiting
- Conditions
- Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
- Interventions
- Drug: HR17031 injection
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 401
- Registration Number
- NCT06881264
- Locations
- 🇨🇳
Peking University People's Hospital, Peking, Beijing, China
A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
Phase 3
Active, not recruiting
- Conditions
- Adult Patients With Type 2 Diabetes
- Interventions
- Drug: HR17031 injection
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 393
- Registration Number
- NCT06871761
- Locations
- 🇨🇳
Shanghai Zhu Xianyi Memorial Hospital, Tianjin Medical University, Tianjin, Tianjin, China
A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia
Phase 2
Recruiting
- Conditions
- Hospital-acquired Bacterial Pneumonia (HABP)Ventilator-associated Bacterial Pneumonia (VABP)
- Interventions
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06841731
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- Hypercholesterolemia and Hyperlipidemia
- Interventions
- Drug: SHR-1209 single-site subcutaneous injectionDrug: SHR-1209 multiple-site subcutaneous injections
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT06837077
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC, Hefei, Anhui, China
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Phase 3
Recruiting
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT06828354
- Locations
- 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
A Trial of SHR0302Base in Patients With Vitiligo
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 152
- Registration Number
- NCT06790862
- Locations
- 🇨🇳
Dermatology Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China
A Study of SHR-4394 Injection in Subjects With Prostate Cancer
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06783829
- Locations
- 🇨🇳
West China Hospital of Sichuan University, ChengDu, Sichuan, China
Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis
Phase 2
Recruiting
- Conditions
- Adolescent Asthma
- Interventions
- Drug: RSS0343 Tabella
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 252
- Registration Number
- NCT06775340
- Locations
- 🇨🇳
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06735144
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Phase 2
Not yet recruiting
- Conditions
- For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT06731829
- Locations
- 🇨🇳
People's Hospital, Peking University, Peking, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath